The Swiss oncology company opens its first office in Canada
Canton Lucerne – The global oncology company is expanding into Canada, making its innovative cancer therapy available throughout its new location.
Novocure is a commercial-stage oncology company dedicated to the advancement of TTF therapy (Tumor Treating Fields) for patients with solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-cancer therapy. Since 2000, the company has grown from one inspired man running experiments in his basement lab to the multinational commercial business it is today.
Novocure has already received authorization for its glioblastoma treatment for the Canadian market. Very few effective treatment options have so far been developed for this most common and particularly aggressive form of primary brain cancer.
The Swiss oncology company chose Montreal, Canada for its new office due to its innovative culture, world-class universities and hospitals, access to top talent and quality of life, and more.
“We are grateful to the many partners in Canada who have contributed to the advancement of our therapy over the years and those who continue to study the science of Tumor Treating Fields today,” said Pritesh Shah, Novocure’s Chief Commercial Officer. “With the establishment of our new office in Montreal, we are focused and committed to driving forward our mission of extending survival in some of the most aggressive forms of cancer as we expand our business in Canada.”
Headquartered in Lucerne, Switzerland, Novocure has US operations across New Hampshire, Pennsylvania, and New York. Specifically in Lucerne, Novocure spearheads its Global Clinical Research activities as well as its Global Supply Chain & Logistics, distributing its product to the EMEA markets. The company employs approximately 100 people in Lucerne, Switzerland.